Cargando…

P13-06. DARPin-based microbicide strategies to block HIV entry

Detalles Bibliográficos
Autores principales:	Mann, A, Krarup, A, Trkola, A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767679/ http://dx.doi.org/10.1186/1742-4690-6-S3-P188

Ejemplares similares

Conformation-dependent recognition of HIV Gp120 by DARPins provides novel possibilities to develop distinct HIV entry inhibitors
por: Mann, AM, et al.
Publicado: (2012)

P02-09. Dissecting the interference of endotoxins with HIV infection of primary CD4 T cell
por: Krarup, A, et al.
Publicado: (2009)

P04-40. Dissecting pre- and post-attachment activity of HIV-1 entry inhibitors and neutralizing antibodies
por: Berlinger, L, et al.
Publicado: (2009)

P13-03. Neutralizing antibody to HIV-1 Env from hyperimmune bovine colostrum as a mucosal microbicide strategy for preventing virus transmission
por: Kramski, M, et al.
Publicado: (2009)

P06-06. Capacity building for HIV vaccine trials in Africa through South-South collaboration
por: Mpendo, J, et al.
Publicado: (2009)

Entry inhibitors as topical microbicides to prevent HIV-1 sexual transmission
por: Moore, John P
Publicado: (2006)

P15-22. Potential synergies between HIV vaccines, microbicides and pre-exposure prophylaxis
por: Sarazin, V, et al.
Publicado: (2009)

P06-08. Building an African HIV preventive trial network
por: Price, MA, et al.
Publicado: (2009)

In Vivo Binding and Retention of CD4-Specific DARPin 57.2 in Macaques
por: Pugach, Pavel, et al.
Publicado: (2010)

P09-02. Selection pressure of neutralizing antibodies and viral escape continues in late stages of the disease
por: Rusert, P, et al.
Publicado: (2009)

P04-37. Kinetic and thermodynamic factors determine HIV-1 neutralizing potency of MPER-specific antibodies
por: Ruprecht, C, et al.
Publicado: (2009)

P07-06. HIV-1 transmission and early evolution: whole genome analysis
por: Herbeck, JT, et al.
Publicado: (2009)

P06-13 Movida.Cronos – eHealth app at primary care to fight sedentary behavior
por: Morouço, Pedro, et al.
Publicado: (2022)

Live microbial microbicides for HIV
por: Hamer, Dean, et al.
Publicado: (2006)

Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% tenofovir microbicide gel trial (CAPRISA004)
por: Burgers, WA, et al.
Publicado: (2012)

P02-06. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine
por: Liu, J, et al.
Publicado: (2009)

Lignosulfonic acid exhibits broad-spectrum anti-HIV and anti-HSV activity and has potential for microbicidal applications
por: Férir, Geoffrey, et al.
Publicado: (2014)

ARV formulated microbicides big promise; as world waits vaccine
por: Ondari, Ronald Orutwa, et al.
Publicado: (2009)

P16-06. Control of HIV-1 by HIV-1 Pol-specific CD8+ T cells in chronically HIV-1-infected Japanese cohort
por: Murakoshi, H, et al.
Publicado: (2009)

Inactivation of cell associated-HIV-1 in breast milk by treatment with the alkyl sulfate microbicide sodium dodecyl sulfate (SDS)
por: Tuaillon, Edouard, et al.
Publicado: (2009)

P09-06 Getting a grip on sitting behaviour
por: Duijvestijn, Marjolein, et al.
Publicado: (2022)

P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection
por: Pegu, A, et al.
Publicado: (2009)

P03.06. Mind body interventions in medical education: a review of the literature
por: Natarajan, A, et al.
Publicado: (2012)

P19-06. The first hypervariable loop and HIV-1 neutralizing antibodies elicited by gp140 env immunogens
por: Ching, LK, et al.
Publicado: (2009)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
por: Ariën, Kevin K, et al.
Publicado: (2011)

Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors
por: Farr, Christina, et al.
Publicado: (2013)

P06-03. The Buea University develops HIV clinical trial capacity within the Cental African Network on TB, HIV/AIDS and malaria, CANTAM
por: Ndumbe, PM, et al.
Publicado: (2009)

P09-06. HIV-1 escape from broadly neutralizing anti-CD4 binding site NAbs during HIV-1 infection
por: Sather, D, et al.
Publicado: (2009)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

P05-06. Masking of MPER epitopes through self-associations
por: Strong, RK, et al.
Publicado: (2009)

P02.06. The effect of massage therapy for breast surgery patients
por: Drackley, N, et al.
Publicado: (2012)

P06-02 Physical activity levels of citizens in Dubrovnik, Croatia
por: Škegro, Dario, et al.
Publicado: (2022)

P01-06 Physical activity and non communicable diseases in France
por: Berjaoui, Roxane, et al.
Publicado: (2022)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

P06-02. High prevalences of HIV, HCV, HBV and Treponema pallidum in male and trans sex workers from Argentina
por: Farías, M dos Ramos, et al.
Publicado: (2009)

P06-09. Web based interviewing system for HIV-behavior research in the settings of vaccine and non vaccine prevention trials
por: Peinado, JE, et al.
Publicado: (2009)

P06-06 Co-development of the national monitoring system for the joy of motion, physical activity and motor skills for pre-school-aged children in Finland
por: Mehtälä, Anette, et al.
Publicado: (2022)

P03-06 The effectiveness of herbal combination as complementary treatment process in a patient with COVID-19
por: Ebadollahinatanzi, A., et al.
Publicado: (2022)

P06-10 To what extent is active mobility practiced by adults in Italy?
por: Minardi, Valentina, et al.
Publicado: (2022)

P06-04. Using referrals from government health centers to expand an HIV discordant couple cohort in Lusaka, Zambia in preparation for vaccine efficacy trials
por: Sitrin, D, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_d4o026umv1a14tomuis4b5o349